Barclays Maintains Overweight on Cytokinetics, Raises Price Target to $110
Barclays analyst Emily Field maintains Cytokinetics (NASDAQ:CYTK) with a Overweight and raises the price target from $95 to $110.
Read original at benzingaStocks · News reference
Cytokinetics Announces Primary Results From Phase 3 Trial Of Aficamten In Non-Obstructive Hypertrophic Cardiomyopathy To Be Presented August 28 At ESC Congress
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 20, 2026, 11:35 AM
- Checked
- Aug 20, 2026, 11:35 AM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
JP Morgan Maintains Overweight on Cytokinetics, Raises Price Target to $103
JP Morgan analyst Tessa Romero maintains Cytokinetics (NASDAQ:CYTK) with a Overweight and raises the price target from $97 to $103.
Read original at benzingaCytokinetics Files Delaware U.S. District Court Claim Against Bristol-Myers Squibb And MyoKardia Seeking Judgment That CYTK Isn't Infringing U.S. Patent No. 12,616,697 And That The ’697 Patent Claims Are Invalid
In the complaint, the Company requests, among other things: a judgment declaring that the Company does not infringe and has not infringed any valid claim of the ’697 patent; a judgment declaring that the claims of the
Read original at benzinga